BACKGROUND: ST-segment elevationmyocardial infarction(STEMI) remains a leading cause of morbidity and mortality around the world. In patients with STEMI undergoing primary percutaneous coronary intervention (PPCI), electrocardiographic measures of ST-segment resolution (STR) may give information about themyocardialperfusion and poor prognosis. To investigate the relation of endocan and galectin-3 levels with STR in STEMI patients Continue reading →

INTRODUCTION: Uninsured patients have decreased access to care, lower rates of percutaneous coronary intervention (PCI), and worse outcomes after acutemyocardial infarction(AMI). Continue reading →

Early on in the COVID-19 pandemic, it appeared that the primary risk of death from the disease was severe pneumonia followed by a cytokine storm. As more is discovered about the disease caused by the SARS-CoV-2, an unexpected cause of death has been identifiedheart attacks and strokes caused by blood clots Continue reading →

It is well established that optimal medical therapy and invasive management are both associated with increased survival after myocardial infarction, author Claudio Montalto, MD, of the University of Pavia in Italy, said in a statement. Therefore, we then examined whether female patients had worse survival strictly due to their sexwhich means genetic and hormonal status, and so onor because of suboptimal treatment. Continue reading →

The Oregon Health Authority this week offered deeper insight into how coronavirus plays out in the state, in particular the underlying medical conditions of those who have succumbed to the illness. The state reviewed records for 73 of the 99 coronavirus-related deaths in Oregon and included the data in its latest update Tuesday. People who died from the illness may have had more than one underlying condition. Continue reading →

Be careful about reading health books. Continue reading →

1. Patients with severely reduced left ventricular ejection fraction with left main, left anterior descending, or multivessel disease who underwent percutaneous coronary intervention demonstrated higher rates of mortality and major adverse cardiovascular events compared to those who underwent coronary artery bypass grafting. Evidence Rating Level:2 (Good) There is insufficient evidence in the literature on outcomes of revascularization strategies for patients with severely reduced left ventricular ejection fraction (LVEF) Continue reading →

SAN CARLOS, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc., (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of United States Patent No. Continue reading →